AUC | P Value | Thresholds | Sensitivity | Specificity | |
---|---|---|---|---|---|
PCNSL vs GBM, metastases | |||||
PSRmax | 0.940 | <.001a | ≥87.00 | 82.1 | 100.0 |
Cho/NAA | 0.835 | <.001a | ≤2.07 | 73.9 | 100.0 |
rCBV | 0.789 | <.001a | ≤2.59 | 92.9 | 63.0 |
Lac/Cr | 0.728 | .006a | ≥0.87 | 87.0 | 56.5 |
Cho/Cr | 0.665 | .01a | ≥2.84 | 56.5 | 77.8 |
Lip/Cr | 0.638 | .32 | |||
PSRmax–Cho/NAA | 0.988 | <.001a | 95.7 | 100.0 | |
GBM vs PCNSL, metastases | |||||
rCBV | 0.911 | <.001a | ≥2.86 | 85.7 | 92.7 |
Cho/NAA | 0.835 | <.001a | ≥2.57 | 100.0 | 73.9 |
Lac/Cr | 0.710 | .40 | |||
Cho/Cr | 0.648 | .68 | |||
PSRmax | 0.633 | .18 | |||
Lip/Cr | 0.629 | .19 | |||
rCBV–Cho/NAA | 0.960 | <.001a | 85.7 | 100.0 | |
Metastases vs PCNSL, GBM | |||||
PSRmax | 0.969 | <.001a | ≤75.00 | 100.0 | 83.3 |
Lac/Cr | 0.957 | <.001a | ≤0.95 | 100.0 | 81.8 |
Cho/Cr | 0.868 | <.001a | ≤1.80 | 92.3 | 81.1 |
Lip/Cr | 0.813 | .02a | ≥2.90 | 100.0 | 64.9 |
rCBV | 0.532 | .51 | |||
PSRmax–Lac/Cr | 0.988 | <.001a | 100.00 | 97.0 | |
PSRmax–Cho/Cr | 1.000 | <.001a | 100.00 | 100.0 |
↵a Significant.